Articles published by CinRx Pharma

CinRx Appoints Rez Halse, PhD, as President to Lead Its Portfolio of Clinical-Stage Development Companies and Accelerate Growth

Today 8:00 EST

From CinRx Pharma

Via Business Wire

CinDome Pharma Announces Enrollment Completion in the envision3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

September 03, 2025

From CinRX Pharma

Via Business Wire

CinFina Pharma Announces Initiation of Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of CIN-110 for the Treatment of Obesity

July 30, 2024

From CinRx Pharma

Via Business Wire

CinRx Pharma Announces Additional $73 Million Financing

May 30, 2024

From CinRx Pharma

Via Business Wire

CinFina Pharma, a CinRx Portfolio Company, Introduces Scientific Advisory Board with Deep Metabolic Expertise

December 14, 2023

From CinRx Pharma

Via Business Wire

CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference

May 08, 2023

From CinRx Pharma

Via Business Wire

CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference

May 02, 2023

From CinRx Pharma

Via Business Wire

CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

April 27, 2023

From CinRx Pharma

Via Business Wire

CinRx Pharma Announces Gavin Samuels, M.D., M.B.A. as Chief Business Officer

October 18, 2022

From CinRx Pharma

Via Business Wire

CinRx Pharma Announces First Study Participant Dosed in CinFina’s Phase I Multiple Ascending Dose (MAD) Study of CIN-109 for the Treatment of Obesity

September 28, 2022

From CinRx Pharma

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.